BR112015005048A8 - métodos para tratar dermatite atópica por administração de antagonista il-4r - Google Patents

métodos para tratar dermatite atópica por administração de antagonista il-4r

Info

Publication number
BR112015005048A8
BR112015005048A8 BR112015005048A BR112015005048A BR112015005048A8 BR 112015005048 A8 BR112015005048 A8 BR 112015005048A8 BR 112015005048 A BR112015005048 A BR 112015005048A BR 112015005048 A BR112015005048 A BR 112015005048A BR 112015005048 A8 BR112015005048 A8 BR 112015005048A8
Authority
BR
Brazil
Prior art keywords
methods
atopic dermatitis
antagonist
administration
treating atopic
Prior art date
Application number
BR112015005048A
Other languages
English (en)
Other versions
BR112015005048A2 (pt
Inventor
Radin Allen
Ming Jeffrey
D Hamilton Jennifer
Ardeleanu Marius
Graham Neil
E Rocklin Ross
C Kirkesseli Stephane
P Weinstein Steven
Kundu Sudeep
Original Assignee
Regeneron Pharma
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015005048(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma, Sanofi Sa filed Critical Regeneron Pharma
Publication of BR112015005048A2 publication Critical patent/BR112015005048A2/pt
Publication of BR112015005048A8 publication Critical patent/BR112015005048A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

resumo patente de invenção: "métodos para tratar dermatite atópica por administração de antagonista il-4r". a presente invenção proporciona métodos para o tratamento de dermatite atópica (ad). são também proporcionados métodos para melhorar um ou mais parâmetros associados a ad (s), e métodos para diminuir o nível de pelo menos um biomarcador associado a ad, em um indivíduo com necessidade do mesmo. os métodos da presente invenção compreendem a administração a um indivíduo em necessidade do mesmo de uma composição farmacêutica compreendendo um antagonista do receptor de interleucina-4 (il-4r) tal como um anticorpo anti-il-4r.
BR112015005048A 2012-09-07 2013-09-04 métodos para tratar dermatite atópica por administração de antagonista il-4r BR112015005048A8 (pt)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201261697972P 2012-09-07 2012-09-07
US201261738715P 2012-12-18 2012-12-18
US201361748588P 2013-01-03 2013-01-03
US201361764624P 2013-02-14 2013-02-14
US201361768229P 2013-02-22 2013-02-22
US201361770091P 2013-02-27 2013-02-27
US201361782420P 2013-03-14 2013-03-14
US201361816191P 2013-04-26 2013-04-26
FR1356759 2013-07-10
PCT/US2013/057898 WO2014039461A1 (en) 2012-09-07 2013-09-04 Methods for treating atopic dermatitis by administering an il-4r antagonist

Publications (2)

Publication Number Publication Date
BR112015005048A2 BR112015005048A2 (pt) 2017-11-21
BR112015005048A8 true BR112015005048A8 (pt) 2018-01-30

Family

ID=50233497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005048A BR112015005048A8 (pt) 2012-09-07 2013-09-04 métodos para tratar dermatite atópica por administração de antagonista il-4r

Country Status (29)

Country Link
US (3) US20140072583A1 (pt)
EP (4) EP3889181B1 (pt)
JP (3) JP6353838B2 (pt)
KR (3) KR102385501B1 (pt)
CN (3) CN104995212A (pt)
AR (1) AR092475A1 (pt)
AU (4) AU2013312868B2 (pt)
BR (1) BR112015005048A8 (pt)
CA (1) CA2883936C (pt)
CY (1) CY1121906T1 (pt)
DK (1) DK2892927T3 (pt)
ES (2) ES2981062T3 (pt)
HK (1) HK1209132A1 (pt)
HR (1) HRP20181227T1 (pt)
HU (2) HUE066738T2 (pt)
IL (1) IL237328B (pt)
LT (1) LT2892927T (pt)
MX (1) MX363193B (pt)
NZ (3) NZ731864A (pt)
PL (1) PL2892927T3 (pt)
PT (1) PT3889181T (pt)
RS (1) RS57520B1 (pt)
RU (2) RU2698907C2 (pt)
SG (2) SG10201701798TA (pt)
SI (1) SI2892927T1 (pt)
TR (1) TR201808181T4 (pt)
TW (3) TWI814575B (pt)
UY (1) UY35013A (pt)
WO (1) WO2014039461A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
CN110624107A (zh) 2012-08-21 2019-12-31 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗或预防哮喘的方法
RS57520B1 (sr) 2012-09-07 2018-10-31 Regeneron Pharma Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r
TWI697334B (zh) * 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20230066127A (ko) 2013-06-21 2023-05-12 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by adding an IL-4R antagonist
AU2015222951B2 (en) * 2014-02-28 2020-06-11 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an IL-4R antagonist
BR112016029581B1 (pt) * 2014-06-17 2022-05-03 Crown Laboratories, Inc Propionibacterium acnes geneticamente modificada, composição e seus usos
TWI745962B (zh) * 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
MX2017006286A (es) * 2014-11-14 2018-01-23 Sanofi Biotechnology Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
DK3277722T3 (da) 2015-04-02 2021-10-11 Intervet Int Bv Antistoffer mod canin interleukin-4 receptor alpha
BR112017022101A2 (pt) 2015-04-14 2018-07-31 Chugai Seiyaku Kabushiki Kaisha composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo
PL3416685T3 (pl) 2016-02-19 2024-08-26 Regeneron Pharmaceuticals, Inc. Sposoby wzmocnienia skuteczności szczepionki przez podawanie antagonisty il-4r
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
MA46098A (fr) 2016-09-01 2019-07-10 Regeneron Pharma Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
KR20230006049A (ko) 2016-09-22 2023-01-10 리제너론 파아마슈티컬스, 인크. Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
RS64550B1 (sr) 2016-09-23 2023-09-29 Hoffmann La Roche Upotreba il-13 antagonista za lečenje atopičnog dermatitisa
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
AU2018359219A1 (en) 2017-10-30 2020-04-23 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing asthma by administering an IL-4R antagonist
CA3079992A1 (en) 2017-10-31 2019-05-09 Oneness Biotech Co. Ltd. Treating ige-mediated allergic diseases
CN111566095B (zh) 2017-11-03 2024-09-27 阿克拉瑞斯治疗股份有限公司 被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法
US20210065248A1 (en) * 2018-01-31 2021-03-04 Medidoc Search Inc. Advertisement presentation method and advertisement presentation system
KR20210010518A (ko) 2018-05-13 2021-01-27 리제너론 파아마슈티컬스, 인크. Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
AU2019317625A1 (en) 2018-08-10 2021-02-18 Aclaris Therapeutics, Inc. Pyrrolopyrimidine ITK inhibitors
WO2020092015A1 (en) * 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
CN111494625B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
JP2022526738A (ja) 2019-03-21 2022-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アレルギーを治療するためのｉｌ－４／ｉｌ－１３経路阻害剤と形質細胞除去の組み合わせ
CN112010977B (zh) * 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 抗白介素4受体(il-4r)的抗体及其应用
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
KR20220044563A (ko) 2019-08-05 2022-04-08 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
US11748800B1 (en) * 2019-09-11 2023-09-05 Life Spectacular, Inc. Generating skin care recommendations for a user based on skin product attributes and user location and demographic data
CN111825766B (zh) 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
CA3161037A1 (en) 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CN115427450A (zh) 2020-03-27 2022-12-02 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
CN116761582A (zh) 2020-06-23 2023-09-15 皇冠实验室有限公司 益生菌皮肤制剂
EP4019090A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-4r
EP4019547A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31
IL303166A (en) 2020-12-23 2023-07-01 Numab Therapeutics AG Antibody variable domains that bind IL-31
US11581084B2 (en) * 2020-12-29 2023-02-14 Kpn Innovations, Llc. Systems and methods for generating an alimentary plan for managing skin disorders
CA3208215A1 (en) * 2021-02-18 2022-08-25 Paul Changelian Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions
JP2024532263A (ja) 2021-08-23 2024-09-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法
WO2023191665A1 (en) * 2022-03-31 2023-10-05 Milaboratory, Limited Liability Company ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF
WO2024076731A1 (en) * 2022-10-06 2024-04-11 Regranion, Llc Methods and compositions for treating hidradenitis suppurativa
WO2024097714A1 (en) 2022-11-01 2024-05-10 Regeneron Pharmaceuticals, Inc. Methods for treating hand and foot dermatitis by administering an il-4r antagonist

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3315427B2 (ja) * 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
DE60130466T2 (de) * 2000-07-26 2008-06-12 Hououdou Co. Ltd. Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP5234445B2 (ja) * 2004-10-05 2013-07-10 源一郎 杣 薬剤
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
RU2453303C1 (ru) * 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
RS57520B1 (sr) 2012-09-07 2018-10-31 Regeneron Pharma Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r

Also Published As

Publication number Publication date
NZ731864A (en) 2022-07-01
SG11201501011WA (en) 2015-03-30
EP4374919A3 (en) 2024-08-21
AU2013312868A1 (en) 2015-03-12
TWI699212B (zh) 2020-07-21
TWI690328B (zh) 2020-04-11
HK1209132A1 (en) 2016-03-24
IL237328A0 (en) 2015-04-30
HUE066738T2 (hu) 2024-09-28
KR102576903B1 (ko) 2023-09-13
RU2015108073A (ru) 2016-10-27
ES2675779T3 (es) 2018-07-12
TW202325341A (zh) 2023-07-01
NZ630178A (en) 2017-06-30
CA2883936A1 (en) 2014-03-13
CY1121906T1 (el) 2020-07-31
EP4374919A2 (en) 2024-05-29
SG10201701798TA (en) 2017-04-27
TWI814575B (zh) 2023-09-01
KR20210095731A (ko) 2021-08-02
AR092475A1 (es) 2015-04-22
CN104995212A (zh) 2015-10-21
AU2013312868B2 (en) 2018-03-22
AU2018204346B2 (en) 2019-10-03
US20170333557A1 (en) 2017-11-23
RS57520B1 (sr) 2018-10-31
JP2015534548A (ja) 2015-12-03
PL2892927T3 (pl) 2018-11-30
JP6637113B2 (ja) 2020-01-29
UY35013A (es) 2014-03-31
NZ748451A (en) 2023-04-28
JP2018154648A (ja) 2018-10-04
KR20150048887A (ko) 2015-05-07
US20230058395A1 (en) 2023-02-23
JP2023082091A (ja) 2023-06-13
TW202412839A (zh) 2024-04-01
TW201822816A (zh) 2018-07-01
AU2018204346A1 (en) 2018-07-05
SI2892927T1 (sl) 2018-10-30
EP3354663A1 (en) 2018-08-01
RU2018131237A (ru) 2018-10-04
IL237328B (en) 2020-06-30
MX363193B (es) 2019-03-14
PT3889181T (pt) 2024-05-29
CN118286430A (zh) 2024-07-05
RU2666630C2 (ru) 2018-09-11
HUE039387T2 (hu) 2018-12-28
EP2892927B1 (en) 2018-05-09
CA2883936C (en) 2022-01-11
EP2892927A1 (en) 2015-07-15
US20140072583A1 (en) 2014-03-13
MX2015002873A (es) 2015-11-13
EP3889181A1 (en) 2021-10-06
EP3889181B1 (en) 2024-04-24
BR112015005048A2 (pt) 2017-11-21
TR201808181T4 (tr) 2018-07-23
WO2014039461A1 (en) 2014-03-13
AU2019279946B2 (en) 2021-07-01
JP6353838B2 (ja) 2018-07-04
TW201414493A (zh) 2014-04-16
ES2981062T3 (es) 2024-10-07
DK2892927T3 (en) 2018-07-16
KR102385501B1 (ko) 2022-04-14
RU2698907C2 (ru) 2019-09-02
AU2019279946A1 (en) 2020-01-16
KR102122708B1 (ko) 2020-06-17
CN118286417A (zh) 2024-07-05
AU2021236538B2 (en) 2023-11-09
KR20220049047A (ko) 2022-04-20
RU2018131237A3 (pt) 2019-03-14
AU2021236538A1 (en) 2021-10-21
HRP20181227T1 (hr) 2018-10-05
LT2892927T (lt) 2018-09-10

Similar Documents

Publication Publication Date Title
BR112015005048A8 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
MX2016011132A (es) Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
NZ707139A (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX365525B (es) Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
BR112014003704A2 (pt) moduladores ror gama
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
UA111357C2 (uk) Аналоги епоксіейкозатриєнової кислоти, композиція на їх основі, застосування для лікування захворювань та спосіб зниження гіпертонії та нефротоксичності (варіанти)
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112021021195A2 (pt) Métodos para tratamento ou prevenção da asma pela administração de um antagonista de il-33
BR112014031841A2 (pt) formulação farmacêutica
BR112015001859A2 (pt) tratamento de inflamação utilizando serelaxina
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
BR112019000837A2 (pt) células miméticas de célula b
EA201590782A1 (ru) Оксирановые амины
CO6602160A2 (es) Terapia de b12 oral
MX2019002801A (es) Uso de una composicion farmaceutica que comprende un anticuerpo anti-il-4r en el tratamiento de la dermatitis atopica.
BR112013033807A2 (pt) formulações pirroloquinolinil-pirrolidin-2,5-diona e métodos para sua preparação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: REGENERON PHARMACEUTICALS, INC. (US) , SANOFI BIOT

B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]